How to understand the association between cystatin C levels and cardiovascular disease: Imbalance, counterbalance, or consequence?

The association of cystatin C with renal function has been studied for more than 25 years. Cystatin C has been described to have a better diagnostic performance than creatinine to assess renal function, particularly to detect small reductions in glomerular filtration rate. Recently, cystatin C has emerged as a strong predictor of incident or recurrent cardiovascular events and adverse outcomes in patients without kidney disease. Furthermore, it has been suggested that cystatin C concentrations are directly related to both inflammation and atherosclerosis. Nevertheless, the link between inflammation, atherogenesis, cardiovascular risk, and cystatin C is still poorly understood. This brief report discusses recent data, contrasting findings and possible mechanisms involved in this interaction.

[1]  K. Okumura,et al.  Cysteine protease cathepsins in atherosclerosis-based vascular disease and its complications. , 2011, Hypertension.

[2]  M. Rudelius,et al.  Histopathological analysis of cellular localization of cathepsins in abdominal aortic aneurysm wall , 2012, International journal of experimental pathology.

[3]  T. Grodzicki,et al.  Kidney function and thickness of carotid intima‐media complex in patients with treated arterial hypertension , 2007, Blood pressure.

[4]  F. Burzotta,et al.  Cystatin C is associated with an increased coronary atherosclerotic burden and a stable plaque phenotype in patients with ischemic heart disease and normal glomerular filtration rate. , 2008, Atherosclerosis.

[5]  W. Koenig,et al.  Cystatin C and cardiovascular risk. , 2009, Clinical chemistry.

[6]  P. Libby,et al.  Cystatin C deficiency in human atherosclerosis and aortic aneurysms. , 1999, The Journal of clinical investigation.

[7]  J. Lages,et al.  Atopic dermatitis in adults: clinical and epidemiological considerations. , 2013, Revista da Associacao Medica Brasileira.

[8]  J. Waltenberger,et al.  Cathepsin enzymes and cystatin C: do they play a role in positive arterial remodeling? , 2009, Stroke.

[9]  F. A. Neves,et al.  Cystatin C May Better Reflect the Effect of Obesity on Renal Function , 2012, Obesity.

[10]  V. Harjola,et al.  Cystatin C: a step forward in assessing kidney function and cardiovascular risk , 2012, Heart Failure Reviews.

[11]  T. Śledziński,et al.  Serum cystatin C in relation to fat mass loss after bariatric surgery. , 2012, Polski przeglad chirurgiczny.

[12]  X. Cheng,et al.  Cysteinyl Cathepsins: Multifunctional Enzymes in Cardiovascular Disease , 2012, Chonnam medical journal.

[13]  V. Lindström,et al.  New antimicrobial cystatin C‐based peptide active against gram‐positive bacterial pathogens, including methicillin‐resistant Staphylococcus aureus and multiresistant coagulase‐negative staphylococci , 2003, APMIS : acta pathologica, microbiologica, et immunologica Scandinavica.

[14]  M. Waltham,et al.  Effect of statins on proteolytic activity in the wall of abdominal aortic aneurysms , 2008, The British journal of surgery.

[15]  T. Dent,et al.  Predicting the risk of coronary heart disease. II: the role of novel molecular biomarkers and genetics in estimating risk, and the future of risk prediction. , 2010, Atherosclerosis.

[16]  S. Reddy,et al.  Chronic inflammatory disorders and accelerated atherosclerosis: chronic kidney disease. , 2011, Current pharmaceutical design.

[17]  A. Hirayama,et al.  Serum cystatin C is associated with early stage coronary atherosclerotic plaque morphology on multidetector computed tomography. , 2011, Atherosclerosis.

[18]  Xuefeng Sun,et al.  Lack of independent relationship between age-related kidney function decline and carotid intima-media thickness in a healthy Chinese population. , 2010, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.

[19]  P. Ferreira,et al.  Correlação entre a cistatina C sérica e marcadores de aterosclerose subclínica em pacientes hipertensos , 2012 .

[20]  K. Bailey,et al.  Estimating the glomerular filtration rate from serum creatinine is better than from cystatin C for evaluating risk factors associated with chronic kidney disease , 2013, Kidney international.

[21]  W. G. Walker,et al.  Plasma aldosterone regulation in anephric man. , 1973, Kidney international.

[22]  P. Libby,et al.  Cystatin C Deficiency Increases Elastic Lamina Degradation and Aortic Dilatation in Apolipoprotein E–Null Mice , 2005, Circulation research.

[23]  S. Urbonavičius,et al.  Higher cystatin C level predicts long-term mortality in patients with peripheral arterial disease. , 2011, Atherosclerosis.

[24]  A. Hamsten,et al.  Genetic approach to the role of cysteine proteases in the expansion of abdominal aortic aneurysms , 2004, The British journal of surgery.

[25]  H. Brenner,et al.  Genotype and Plasma Concentration of Cystatin C in Patients With Coronary Heart Disease and Risk for Secondary Cardiovascular Events , 2005, Arteriosclerosis, thrombosis, and vascular biology.

[26]  Harlan M Krumholz,et al.  Renal impairment and outcomes in heart failure: systematic review and meta-analysis. , 2006, Journal of the American College of Cardiology.

[27]  J. Lindholt,et al.  Cystatin C deficiency is associated with the progression of small abdominal aortic aneurysms , 2001, The British journal of surgery.

[28]  T. Çaycı,et al.  Relationship of cystatin C with coronary artery disease and its severity , 2013, Coronary artery disease.

[29]  P. Ridker,et al.  Plasma levels of cystatin-C and mannose binding protein are not associated with risk of developing systemic atherosclerosis , 2001, Vascular medicine.

[30]  A. Sinha,et al.  Association of plasma cystatin C levels with angiographically documented coronary artery disease in patients of Indian origin. , 2012, Journal of cardiology.

[31]  K. Clément,et al.  Potential Contribution of Adipose Tissue to Elevated Serum Cystatin C in Human Obesity , 2009, Obesity.

[32]  T. Dent,et al.  Predicting the risk of coronary heart disease I. The use of conventional risk markers. , 2010, Atherosclerosis.

[33]  Qin M. Chen,et al.  Cystatin C increases in cardiac injury: a role in extracellular matrix protein modulation. , 2010, Cardiovascular research.

[34]  Harold I Feldman,et al.  Estimating glomerular filtration rate from serum creatinine and cystatin C. , 2012, The New England journal of medicine.

[35]  J. Björk,et al.  Cystatin C, a marker for successful aging and glomerular filtration rate, is not influenced by inflammation , 2011, Scandinavian journal of clinical and laboratory investigation.

[36]  B. Astor,et al.  Novel markers of kidney function as predictors of ESRD, cardiovascular disease, and mortality in the general population. , 2012, American journal of kidney diseases : the official journal of the National Kidney Foundation.

[37]  A. M. Santos,et al.  Cystatin C and inflammatory markers in kidney transplant recipients. , 2011, Revista da Associacao Medica Brasileira.

[38]  M. Shlipak,et al.  Occult chronic kidney disease among persons with hypertension in the United States: data from the national health and nutrition surveys 1988–1994 and 1999–2002 , 2013, Journal of hypertension.

[39]  M. Bastos,et al.  Monitoring renal function: measured and estimated glomerular filtration rates - a review. , 2010, Brazilian journal of medical and biological research = Revista brasileira de pesquisas medicas e biologicas.

[40]  William Wijns,et al.  [Guidelines for the diagnosis and treatment of non-ST-segment elevation acute coronary syndromes]. , 2007, Revista portuguesa de cardiologia : orgao oficial da Sociedade Portuguesa de Cardiologia = Portuguese journal of cardiology : an official journal of the Portuguese Society of Cardiology.

[41]  M. Shlipak,et al.  Update on cystatin C: new insights into the importance of mild kidney dysfunction , 2006, Current opinion in nephrology and hypertension.

[42]  P. Libby,et al.  Cystatin C deficiency promotes inflammation in angiotensin II-induced abdominal aortic aneurisms in atherosclerotic mice. , 2010, The American journal of pathology.

[43]  J. Nilsson,et al.  Lack of the Cysteine Protease Inhibitor Cystatin C Promotes Atherosclerosis in Apolipoprotein E–Deficient Mice , 2005, Arteriosclerosis, thrombosis, and vascular biology.

[44]  Wen-Hung Huang,et al.  Impact of Elevated Cystatin C Level on Cardiovascular Disease Risk in Predominantly High Cardiovascular Risk Populations: A Meta-Analysis , 2010, Circulation. Cardiovascular quality and outcomes.

[45]  L. Hansson,et al.  Human Evidence That the Cystatin C Gene Is Implicated in Focal Progression of Coronary Artery Disease , 2004, Arteriosclerosis, thrombosis, and vascular biology.

[46]  Xiantao Song,et al.  Relationship between plasma cathepsin S and cystatin C levels and coronary plaque morphology of mild to moderate lesions: an in vivo study using intravascular ultrasound. , 2009, Chinese medical journal.

[47]  P. Puddu,et al.  Relationships among hyperuricemia, endothelial dysfunction and cardiovascular disease: molecular mechanisms and clinical implications. , 2012, Journal of cardiology.

[48]  D. Levy,et al.  Association of visceral and subcutaneous adiposity with kidney function. , 2008, Clinical journal of the American Society of Nephrology : CJASN.

[49]  J. Higaki,et al.  Association between cystatin C and inflammation in patients with essential hypertension , 2010, Clinical and Experimental Nephrology.